BIOGGIO, Switzerland--(BUSINESS WIRE)--Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced that it has appointed Dr. Johanna Holldack as its new Chief Executive Officer.
Dr. Holldack was previously Chief Executive Officer of Borean Pharma, but has also had extensive management experience in a number of other life sciences companies. Her previous posts included Chief Operation’s Officer at MediGene AG in Munich, Germany, Vice President of Global Vaccines and Therapeutics at Chiron Corp. in Emeryville, USA and Head of Clinical Research and Development at German Behringwerke AG.
Welcoming Dr. Holldack as the new CEO, Dr. Thomas Hecht, Chairman of the Telormedix board, commented: “With more than 20 years experience of working in the pharmaceutical and biotech industry, Johanna brings with her a very strong commercial background with broad scientific and medical expertise. We are delighted to welcome Johanna to the team and believe that her experience will help further Telormedix’s development as a company.”
Commenting on her appointment, Dr. Holldack said: “It is great to be stepping into the role of CEO at Telormedix at such a pivotal stage in its development as a company. I am really looking forward to moving Telormedix on to its new footing as a clinical stage company with a growing pipeline of products that use innate immunity to treat cancer and other diseases.”
Telormedix is a relatively young Swiss company, founded in 2008, but has advanced quickly and will soon enter the clinic. It was originally cofounded by among others Prof. Rolf Zinkernagel, Nobel Prize laureate and former Director of the Institute of Experimental Immunology of the University of Zurich and by Prof. Dennis Carson, Director of Moores Cancer Center at UCSD. Dr. Lorenzo Leoni was another cofounder who also served as CEO before stepping down recently. Each of these co-founders still maintain a strong connection with the company and Telormedix works closely with the laboratory of Professor Carson in sourcing its innovative pipeline of therapeutic candidates. Telormedix is financed by an international consortium of venture capitalists including Aravis Venture (Basel, Switzerland), Proquest Investments (Princeton-San Diego, USA), BSI S.A. (Lugano, Switzerland), Nextech Venture (Zurich Switzerland) and Generali Insurance Group (Italy).
Dr. Holldack earned her medical degree from the Georg-August-University in Göttingen, Germany and is a Board Certified paediatrician. She spent more than a decade as a research associate and assistant professor in paediatrics and paediatric oncology and haematology at the universities of Essen and Freiburg in Germany. In addition, she has held positions as a research fellow at the Deutsche Krebshilfe and a research associate at Harvard Medical School in Boston, USA.
About Telormedix
Telormedix is a clinical stage biopharmaceutical company founded in 2008 and focused on targeted immunity in the treatment of cancer and other diseases. The Company’s lead product, TMX-101, is entering the clinic for the localised treatment of bladder cancer, a disease of unmet medical need. TMX-101 is a new formulation of a clinically active small molecule compound specifically optimized for treating bladder cancer. Telormedix also has an additional pipeline of product candidates targeting cancer and autoimmune diseases. The Company’s discovery capability, managed under an exclusive licensing agreement, draws on years of experience and the world class research standing of its academic partner. Located in Switzerland, Telormedix is led by a highly experienced management team and backed by a consortium of leading global investors.
Further information on Telormedix can be found at www.telormedix.com
Contact:
Telormedix SA Johanna Holldack, CEO t: +41 (0)91 610 7000 e: jholldack@telormedix.com or College Hill Life Sciences Douglas Pretsell, Account Director, Munich Bureau Chief t: +49 (0)89 57 00 18 06 e: douglas.pretsell@collegehill.com
